ArticleFrontiers in medicine2025
Case Report: Human metapneumovirus infection leading to septic shock in an adult with COPD and morbid obesity.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human metapneumovirus (hMPV) is an emerging respiratory pathogen causing illnesses from mild upper respiratory infection to severe pneumonia, particularly in high-risk adults. Although primarily recognized in pediatrics, hMPV is increasingly reported as a cause of acute respiratory failure in adults with chronic lung disease and obesity. Case: A 58-year-old man with morbid obesity and chronic obstructive pulmonary disease presented with acute respiratory failure and viral septic shock. Molecular testing of bronchoalveolar lavage (BioFire® FilmArray®) identified Conclusion: hMPV can trigger severe respiratory failure and multiorgan dysfunction in adults with chronic respiratory comorbidities. Early molecular diagnosis is crucial to guide management and limit unnecessary antimicrobial exposure. The absence of specific antivirals underscores the need for continued research into targeted treatments and preventive vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.